(Q45239422)

11 December 2017

title

Clinicopathological characteristics and outcomes of patients with crescentic lupus nephritis (English)

1 reference

11 December 2017

Feng Yu

1

1 reference

11 December 2017

Ying Tan

2

1 reference

11 December 2017

Gang Liu

3

1 reference

11 December 2017

Su-xia Wang

4

1 reference

11 December 2017

Wan-zhong Zou

5

1 reference

11 December 2017

Ming-hui Zhao

6

1 reference

11 December 2017

language of work or name

English

0 references

publication date

29 April 2009

1 reference

11 December 2017

1 reference

11 December 2017

volume

76

1 reference

11 December 2017

issue

3

1 reference

11 December 2017

page(s)

307-317

1 reference

The classification of glomerulonephritis in systemic lupus erythematosus revisited

11 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.136

7 January 2021

Lupus nephritis: a challenging cause of rapidly progressive crescentic glomerulonephritis.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.136

7 January 2021

Antineutrophil cytoplasmic autoantibodies in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.136

7 January 2021

Successful treatment of rapidly progressive lupus nephritis associated with anti-MPO antibodies by intravenous immunoglobulins

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.136

7 January 2021

Membranous lupus nephritis with antineutrophil cytoplasmic antibody-associated segmental necrotizing and crescentic glomerulonephritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.136

7 January 2021

SLE and rapidly progressive glomerulonephritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.136

7 January 2021

Antilactoferrin antibody in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.136

7 January 2021

Antineutrophil cytoplasmic autoantibodies (ANCA) and their target antigens in Chinese patients with lupus nephritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.136

7 January 2021

Autoantibodies to myeloperoxidase in idiopathic and drug-induced systemic lupus erythematosus and vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.136

7 January 2021

Anti-neutrophil cytoplasmic antibody in patients with systemic lupus erythematosus is unrelated to clinical features

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.136

7 January 2021

Antineutrophil cytoplasmic antibodies in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.136

7 January 2021

Pauci-immune necrotizing and crescentic glomerulonephritis in a patient with systemic lupus erythematosus.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.136

7 January 2021

Necrotizing and crescentic lupus nephritis with antineutrophil cytoplasmic antibody seropositivity

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.136

7 January 2021

A boy with consecutive development of SLE and Wegener granulomatosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.136

7 January 2021

MIP-1alpha and MCP-1 contribute to crescents and interstitial lesions in human crescentic glomerulonephritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.136

7 January 2021

Defibrination with ancrod in nephrotoxic nephritis in rabbits

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.136

7 January 2021

Fibrin independent proinflammatory effects of tissue factor in experimental crescentic glomerulonephritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.136

7 January 2021

Renal expression of tissue factor pathway inhibitor and evidence for a role in crescentic glomerulonephritis in rabbits

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.136

7 January 2021

Activated (IL-2R+) intraglomerular mononuclear cells in crescentic glomerulonephritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.136

7 January 2021

Glomerular expression of CD80 and CD86 is required for leukocyte accumulation and injury in crescentic glomerulonephritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.136

7 January 2021

A pathogenetic role for mast cells in experimental crescentic glomerulonephritis.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.136

7 January 2021

Podocytes Populate Cellular Crescents in a Murine Model of Inflammatory Glomerulonephritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.136

7 January 2021

Effects of mycophenolate mofetil for patients with crescentic lupus nephritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.136

7 January 2021

Outcome of relapse in lupus nephritis: roles of reversal of renal fibrosis and response of inflammation to therapy.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.136

7 January 2021

Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.136

7 January 2021

Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.136

7 January 2021

Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.136

7 January 2021

Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.136

7 January 2021

Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.136

7 January 2021

Predicting renal outcomes in severe lupus nephritis: contributions of clinical and histologic data

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.136

7 January 2021

Immune complex deposits in ANCA-associated crescentic glomerulonephritis: a study of 126 cases

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.136

7 January 2021

A new morphologic index for the evaluation of renal biopsies in lupus nephritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.136

7 January 2021

Induction therapies for class IV lupus nephritis with non-inflammatory necrotizing vasculopathy: mycophenolate mofetil or intravenous cyclophosphamide

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.136

7 January 2021

Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.136

7 January 2021

Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.136

7 January 2021

Induction treatment of proliferative lupus nephritis with leflunomide combined with prednisone: a prospective multi-centre observational study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.136

7 January 2021

Sequential therapies for proliferative lupus nephritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.136

7 January 2021

Detection rate and antigenic specificities of antineutrophil cytoplasmic antibodies in chinese patients with clinically suspected vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.136

7 January 2021

Characteristics and prognosis of Chinese patients with anti-glomerular basement membrane disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.136

7 January 2021

Identifiers

DOI

10.1038/KI.2009.136

1 reference

Dimensions Publication ID

11 December 2017

1050739794

0 references

1 reference